Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO vs Methylprednisolone in Spinal Shock
NCT00561067Phase 3Terminated
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Apr 2008
- Primary completion
- Jul 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of erythropoietin in spinal cord injury (SCI), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Improvement of ASIA Impairment Scale of at least 1 grade at 3 months. Started Apr 2008; status: terminated.
02
Drugs
erythropoietin
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT00561067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561067.